What is the mechanism of Ketamine's rapid‐onset antidepressant effect? A concise overview of the surprisingly large number of possibilities

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Pharmacy and Therapeutics

• Publication date

  2017-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jcpt.12497PMID 28111761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Double-blind, Placebo-Controlled Study

  2017cited by this paper
• Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test

  2015cited by this paper
• Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.

  2015cited by this paper
• Rapid‐onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression

  2015influential reference
• Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.

  2015cited by this paper
• On the significance of elektroconvulsive therapy in the treatment of severe mental diseases

  2015cited by this paper
• Ketamine and other potential glutamate antidepressants.

  2015cited by this paper
• Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

  2015influential reference
• Faster, better, stronger: towards new antidepressant therapeutic strategies.

  2015cited by this paper
• Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents.

  2015cited by this paper
• The promise of ketamine for treatment‐resistant depression: current evidence and future directions

  2015cited by this paper
• The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.

  2015cited by this paper
• Immunomodulatory activity of ketamine in human astroglial A172 cells: Possible relevance to its rapid antidepressant activity.

  2015cited by this paper
• Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

  2015cited by this paper
• Study of antidepressant drugs in GPR39 (zinc receptor⁻/⁻) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists.

  2015cited by this paper
• Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.

  2015cited by this paper
• Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

  2015cited by this paper
• Short-term escitalopram treatment and hippocampal volume

  2014cited by this paper
• Ethiopathogenesis of Depressive Disorders

  2014cited by this paper
• GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine

  2014cited by this paper
• Nicotinic α7 receptor activation selectively potentiates the function of NMDA receptors in glutamatergic terminals of the nucleus accumbens

  2014cited by this paper
• Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

  2014influential reference
• Targeting of NMDA receptors in the treatment of major depression.

  2014influential reference
• Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan

  2014influential reference
• NMDA Receptor Antagonists for Treatment of Depression

  2013cited by this paper
• Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression.

  2013cited by this paper
• Conceptual Confluence: The Kynurenine Pathway as a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression

  2013cited by this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders

  2013cited by this paper
• Predictors of first lifetime onset of major depressive disorder in young adulthood.

  2013cited by this paper
• Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

  2013cited by this paper
• Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

  2013cited by this paper
• Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.

  2013cited by this paper
• A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

  2013cited by this paper
• Signaling pathways underlying the rapid antidepressant actions of ketamine.

  2012cited by this paper
• Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

  2012cited by this paper
• Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

  2012cited by this paper
• Synaptic mechanisms underlying rapid antidepressant action of ketamine.

  2012cited by this paper
• The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder.

  2011cited by this paper
• Effects of Venlafaxine and Escitalopram Treatments on NMDA Receptors in the Rat Depression Model

  2011cited by this paper
• Dextromethorphan as a potential rapid-acting antidepressant.

  2011cited by this paper
• Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission?

  2011cited by this paper
• Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex.

  2010cited by this paper
• Overview of the Genetics of Major Depressive Disorder

  2010cited by this paper
• mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

  2010cited by this paper
• Substance Abuse Treatment, Prevention, and Policy Treatment of Alcohol Dependence in Patients with Co-morbid Major Depressive Disorder – Predictors for the Outcomes with Memantine and Escitalopram Medication

  2008cited by this paper
• How much cognitive therapy, for which patients, will prevent depressive relapse?

  2008cited by this paper
• Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy

  2008cited by this paper
• An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

  2008cited by this paper
• Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.

  2007cited by this paper
• An Open-label, Flexible-Dose Study of Memantine in Major Depressive Disorder

  2007cited by this paper
• The NMDA receptor as a therapeutic target in major depressive disorder.

  2007cited by this paper
• Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.

  2006cited by this paper
• A neurotrophic model for stress-related mood disorders.

  2006cited by this paper
• A double-blind, placebo-controlled study of memantine in the treatment of major depression.

  2006cited by this paper
• An open-label trial of riluzole in patients with treatment-resistant major depression.

  2004cited by this paper
• The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys

  2003cited by this paper
• The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity

  2003cited by this paper
• Amantadine as augmentation therapy in the management of treatment-resistant depression

  2003cited by this paper
• NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia

  2002cited by this paper
• Endogenous kynurenines as targets for drug discovery and development

  2002cited by this paper
• Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant α7 and α4β2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes

  2001cited by this paper
• Kynurenines in the CNS: from endogenous obscurity to therapeutic importance.

  2001cited by this paper
• Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes.

  2001cited by this paper
• Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial.

  2000cited by this paper
• Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain

  1998cited by this paper
• The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity

  1998cited by this paper
• Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors.

  1998cited by this paper
• Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy

  1995cited by this paper
• [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders].

  1993cited by this paper
• Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity.

  1992cited by this paper
• Nicotinylalanine Increases the Formation of Kynurenic Acid in the Brain and Antagonizes Convulsions

  1992cited by this paper
• FLUOXETINE TREATMENT INDUCES STRUCTURAL LASTICITY AND SELECTIVE CHANGES IN GLUTAMATE RECEPTOR UBUNITS IN THE RAT CEREBRAL CORTEX

  year unknowncited by this paper

• A systematic review and meta-analysis on ketamine use and postoperative delirium in older patients undergoing spine or orthopedic surgery

  2026cites this paper
• Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time

  2026cites this paper
• Repurposing Existing Drugs for the Treatment of Post-Traumatic Stress Disorder

  2025cites this paper
• Ganoderma lucidum: An Emerging Nutritional Approach to Manage Depression

  2025cites this paper
• Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic

  2025cites this paper
• Ketamine—From an Anesthetic to a Psychiatric Drug: Mechanisms of Action, Clinical Applications and Potential Risks

  2025cites this paper
• Role of ketamine in the treatment of substance use disorders: A systematic review.

  2025cites this paper
• Ketamine-Assisted Recovery (KARE): protocol for an open-label pilot trial of ketamine-assisted psychotherapy for publicly insured patients with methamphetamine use disorder and HIV risks

  2025cites this paper
• A Preliminary Approach to Oral Low-Dose Ketamine Self-Administration in Mice (Mus musculus)

  2025cites this paper
• Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction.

  2025cites this paper
• Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression

  2024cites this paper
• Pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder: A systematic review.

  2024cites this paper
• Metabolomic biomarkers for (R, S)‐ketamine and (S)‐ketamine in treatment‐resistant depression and healthy controls: A systematic review

  2024cites this paper
• Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders

  2024cites this paper
• Pre-adolescence repeat exposure to sub-anesthetic doses of ketamine induces long-lasting behaviors and cognition impairment in male and female rat adults

  2024cites this paper
• Activation of ventral hippocampal CB1 receptors inhibits ketamine-induced anxiogenic-like behavior: Alteration of BDNF/c-Fos levels in the mouse hippocampus.

  2023cites this paper
• Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder

  2023influential citation
• Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions

  2023cites this paper
• Pharmacotherapy: Ketamine and Esketamine.

  2023cites this paper
• Increased BDNF and hippocampal dendritic spine density are associated with the rapid antidepressant-like effect of iron-citalopram and iron-imipramine combinations in mice.

  2023cites this paper
• SYSTEMATIC REVIEW AND META-ANALYSIS Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis

  2022cites this paper
• A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis.

  2022cites this paper
• Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

  2022cites this paper
• S-ketamine exerts sex- and dose-dependent anti-compulsive-like effect as monotherapy or in augmentation to fluoxetine.

  2022cites this paper
• Depression in Adolescence and Brain-Derived Neurotrophic Factor

  2022cites this paper
• Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors

  2022cites this paper
• From a Symptom-Based to a Mechanism-Based Pharmacotherapeutic Treatment in Complex Regional Pain Syndrome

  2022cites this paper
• Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions

  2021cites this paper
• Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses

  2021cites this paper
• Role of Ketamine in the Treatment of Psychiatric Disorders.

  2021cites this paper
• Development of new rapid-action treatments in mood disorders

  2021cites this paper
• Effect of intravenous low‐dose S‐ketamine on pain in patients with Complex Regional Pain Syndrome: A retrospective cohort study

  2021cites this paper
• Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

  2021influential citation
• Ketamine for Bipolar Depression: A Systematic Review

  2021cites this paper
• Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?

  2021cites this paper
• Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers

  2021cites this paper
• Antidepressant Actions of Ketamine: Potential Role of L-Type Calcium Channels.

  2021cites this paper
• Overview of ketamine for major depression: efficacy and effectiveness

  2021cites this paper
• Beating Pain with Psychedelics: Matter over Mind?

  2021cites this paper
• Therapeutic Mechanisms of Ketamine.

  2020cites this paper
• mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects.

  2020cites this paper
• AMPA receptor-mTORC1 signaling activation is required for neuroplastic effects of LY341495 in rat hippocampal neurons

  2020cites this paper
• NMDA Antagonists and Their Role in the Management of Bipolar Disorder: a Review

  2020cites this paper
• Type 3 adenylyl cyclase in the main olfactory epithelium participates in depression-like and anxiety-like behaviours.

  2020cites this paper
• A Review of Nonanesthetic Uses of Ketamine

  2020cites this paper
• Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers

  2020cites this paper
• Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression

  2020cites this paper
• Molecular mechanisms for the antidepressant-like effects of a low-dose ketamine treatment in a DFP-based rat model for Gulf War Illness.

  2020cites this paper
• Increased use of ketamine for the treatment of depression: Benefits and concerns.

  2020cites this paper
• The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication

  2020cites this paper
• Intravenous Ketamine Administered as Patient Controlled Analgesia and Continuous Infusion for Central Pain Syndrome

  2020cites this paper
• Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.

  2020cites this paper
• Algo más que monoaminas en el tratamiento de la depresión: Mecanismos neurobiológicos emergentes de los antidepresivos del siglo XXI

  2020cites this paper
• EFFECT OF SINGLE DOSE OF KETAMINE IN PATIENTS OF MAJOR DEPRESSIVE DISORDER-A PAKISTANI PERSPECTIVE

  2020cites this paper
• Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism

  2019cites this paper
• Effects of Repeated Intravenous Ketamine in Treatment-Resistant Geriatric Depression: A Case Series

  2019cites this paper
• Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant

  2019cites this paper
• [Neurotrophic mechanisms of psychedelic therapy].

  2019cites this paper
• Characterization of the Wistar-Kyoto rat model of depression in the context of hippocampal synaptic plasticity and ketamine’s antidepressant properties

  2019influential citation
• Rapid-acting antidepressants.

  2019cites this paper
• Selecting an Appropriate Animal Model of Depression

  2019cites this paper
• Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events.

  2018cites this paper
• Case Report of Subanesthetic Intravenous Ketamine Infusion for the Treatment of Neuropathic Pain and Depression with Suicidal Features in a Pediatric Patient

  2018cites this paper
• Rapid-Acting Antidepressants.

  2018cites this paper
• Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review

  2018cites this paper
• A Review of the Mechanism of Antagonism of N-methyl-D-aspartate Receptor by Ketamine in Treatment-resistant Depression

  2018cites this paper
• Biological Mechanisms of Cancer-Induced Depression

  2018cites this paper
• A reappraisal of the mechanisms of action of ketamine to treat complex regional pain syndrome in the light of cortical excitability changes.

  2018cites this paper
• Substances of Abuse and Hallucinogenic Activity: The Glutamatergic Pathway - Focus on Ketamine

  2018cites this paper
• Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments

  2018cites this paper
• Leptin in depression: a potential therapeutic target

  2018cites this paper
• Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double‐blind, randomised clinical trial

  2018cites this paper
• Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches.

  2018cites this paper
• Ketamine as a rapid‐acting agent for suicidal ideation: A meta‐analysis

  2017cites this paper
• Receptor distribution studies

  2017cites this paper
• Potential Pharmacokinetic and Pharmacodynamic Drug Interactions

  2017cites this paper
• Hydroxynorketamine: Implications for the NMDA Receptor Hypothesis of Ketamine’s Antidepressant Action

  2017cites this paper
• Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action.

  2017cites this paper
• Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions.

  2017cites this paper